Skip to main content

Primary Immune Deficiency Disorder

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)
NCT01458171 | PHASE 3 | INTERVENTIONAL

The objective of this study is to assess the long-term safety, tolerability, and efficacy of IgPro20 in subjects with primary immunodeficiency (PID) as a follow-up to the pivotal study ZLB06_002CR (NCT01199705).

Trial Information
9 Sites
23 Participants
Recruiting
18 Years to 75 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Study site
Nagoya city,Aichi Pref.,Japan,466-8560
Study site
Chiba city,Chiba Pref.,Japan,260-8677
Study site
Fukuoka city,Fukuoka,Japan,812-8582
Study site
Gifu city,Gifu Pref.,Japan,502-8558
Study site
Sapporo city,Hokkaido,Japan,060-8648
Study site
Moriguchi city,Osaka,Japan,570-8507
Study site
Koshigaya city,Saitama Pref.,Japan,343-8555
Study site
Tokorozawa city,Saitama Pref.,Japan,359-8513
Study site
Bunkyo-ku,Tokyo Metropolitan,Japan,113-8519

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov